Working… Menu

Exercise for Advanced Prostate Cancer: a Multicomponent Feasibility Trial (EXACT)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03658486
Recruitment Status : Recruiting
First Posted : September 5, 2018
Last Update Posted : April 5, 2019
HSC Public Health Agency
Information provided by (Responsible Party):
Gillian Prue, Queen's University, Belfast

Brief Summary:
This feasibility study will investigate whether men with metastatic prostate cancer can take part in and progress through a home-based exercise program. This study will evaluate the effects of exercise on a range of disease and treatment-related outcomes.

Condition or disease Intervention/treatment Phase
Prostate Cancer Metastatic Castration-resistant Prostate Cancer Other: Exercise Not Applicable

Detailed Description:
This 12 week multicomponent, tailored, progressive program will consist of both moderate intensity walking and strengthening exercises at home. This single centre, single arm study will incorporate a behavioural change consultation at baseline and weekly behavioural support throughout. This study will follow-up patients at 24 weeks to determine exercise maintenance. Outcome measures will be completed at baseline, 12 and 24 weeks. A qualitative evaluation will be conducted after the 24 week follow-up to determine impact, patient experience and measures that might assist in refining the program.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 30 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Other
Official Title: Exercise for Advanced Prostate Cancer: a Multicomponent Feasibility Trial in Men With Metastatic Castrate-Resistant Prostate Cancer
Actual Study Start Date : February 19, 2019
Estimated Primary Completion Date : October 2021
Estimated Study Completion Date : October 2021

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
12 weeks of progressive, home-based, moderate intensity, aerobic and strengthening exercise. Aerobic exercise will be completed 5 days per week, commencing with a single 10 minute bout and progressing to 30 minutes of continuous brisk walking at week 12. Strengthening exercises will involve whole body activities and commence with 1 set of each exercise (8-15 repetitions) and progress to 3 sets. The strengthening exercises will gradually progress in difficulty throughout the program.
Other: Exercise
Exercise programs will be individually tailored to the capabilities of each participant and gradually progressed accordingly. Each patient will be assigned a moderate intensity walking and strengthening program to complete at home. At baseline, 12 and 24 weeks patients will wear an accelerometer to determine activity levels. At these time points, patients will also complete a physical fitness assessment (timed sit-to-stand and six minute walking tests) and a range of quality of life questionnaires. At baseline, patients will receive a behaviour change consultation and continued support throughout the intervention. Each patient will receive a pedometer during the home-based, unsupervised regime to monitor step count and they are expected to complete a daily physical activity diary. Upon completion of the 24 week follow-up, patients will be invited to partake in semi-structured interviews to determine the effectiveness of the program and their experience throughout.

Primary Outcome Measures :
  1. Feasibility - recruitment. [ Time Frame: At baseline. ]
    The number of participants that agree to participate or are excluded.

  2. Feasibility - adherence to the exercise intervention. [ Time Frame: Throughout the 24 week study period. ]
    Determine the percentage of patients adhering to the program and the weekly behavioral consultation sessions.

  3. Feasibility - attrition rates. [ Time Frame: Throughout the 24 week study period. ]
    The number of patients that withdraw.

  4. Feasibility - safety / adverse events. [ Time Frame: Monitored throughout the 24 week study period. ]
    Any safety / adverse events, in general or in relation to the exercise program, will be documented by the research team.

  5. Feasibility - patient experience. [ Time Frame: Following the study conclusion at 24 weeks. ]
    Determined by qualitative evaluation, using semi-structured interviews, to assess experiences, accessibility and acceptability of the exercise intervention.

Secondary Outcome Measures :
  1. Anthropometric assessment. [ Time Frame: At baseline, 12 and 24 weeks. ]
    Height will be measured in cm and body weight in kg, which will be combined to report BMI in kg/m(squared).

  2. Hip and waist circumference analysis. [ Time Frame: At baseline, 12 and 24 weeks. ]
    Hip and waist circumference will be measured in cms.

  3. Functional ability assessment. [ Time Frame: At baseline, 12 and 24 weeks. ]
    The amount of repetitions achieved during a 30 second sit-to-stand test will be recorded.

  4. Physical fitness assessment. [ Time Frame: At baseline, 12 and 24 weeks. ]
    Distance covered in meters during a six minute walk test will be recorded.

  5. Objectively measure of physical activity levels. [ Time Frame: At baseline, 12 and 24 weeks. ]
    Patients will wear an accelerometer for 7 full days.

  6. Perceived physical activity levels. [ Time Frame: At baseline, 12 and 24 weeks. ]
    Patients will complete an International Physical Activity Questionnaire (IPAQ-SF). This questionnaire will comprise 4 generic items to obtain comparable health-related physical activity. Patients will detail the number of days, hours and minutes that they undertake (1) vigorous exercise (2) moderate exercise (3) walking exercise and (4) sitting. Total physical activity will be generated and monitored for improvement or decline.

  7. Cancer-related fatigue by questionnaire. [ Time Frame: At baseline, 12 and 24 weeks. ]
    Fatigue will be measured by the Functional Assessment of Cancer Therapy - Fatigue (FACIT-Fatigue) questionnaire. Patients will score several fatigue items over the past 7 days on a scale (0 = not at all; 4 = very much), generating a total (0 - 52) with higher scores linked to greater quality of life.

  8. Quality of life will be measured using a questionnaire. [ Time Frame: At baseline, 12 and 24 weeks. ]
    Quality of life will be measured by the Functional Assessment of Cancer Therapy - Prostate (FACT-P) questionnaire. Patients will score a series of questions (0 = not at all; 4 = very much) in five sections (physical well-being; social/family well-being; emotional well-being; functional well-being; additional concerns) for the past 7 days. Higher scores will suggest better quality of life.

  9. Quality of life will be measured using questionnaires. [ Time Frame: At baseline, 12 and 24 weeks. ]
    Quality of life will be measured by the EuroQOL Five Dimension Questionnaire (EQ5D). Patients will select a level of difficulty (I have no - I have extreme) on that particular days health for mobility, self-care, usual activities, pain / discomfort and anxiety / depression. Patients will then rate 'how good' or 'how bad' their health is on that day using a 100 point scale (0 = worst health you can imagine; 100 = best health you can imagine).

  10. Pain will be measured through a questionnaire. [ Time Frame: At baseline, 12 and 24 weeks. ]
    Bone pain will be monitored using the Brief Pain Inventory Short Form (BPI-SF).

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Histologically documented adenocarcinoma of the prostate with progressive systemic metastatic disease despite castrate levels of testosterone (<50ng/dL).
  • At enrolment, patients must have demonstrated progressive disease since the most recent change in therapy.
  • Patients must be on ADT with a GnRH agonist/antagonist or prior bilateral orchiectomy. All patients must be on ADT during the study period.
  • ≥ 4 weeks since last surgery and fully recovered.
  • No known contraindications to moderate intensity exercise such as (but not limited to) brain metastases, acute congestive heart failure, unstable angina, serious or non-healing wound, peripheral neuropathy greater than or equal to Grade 3. Recent myocardial infarction.
  • Age ≥ 18 years.
  • ECOG performance status 0-2.
  • Medical clearance by treating clinician.

Exclusion Criteria:

  • Men currently exceeding ACSM recommended exercise guidelines (150 mins of moderate and/or 60 mins of high intensity exercise per week).
  • Men with brain metastases.
  • Men with a currently active second malignancy other than non-melanoma skin cancer.
  • Congestive heart failure or recent serious cardiovascular event.
  • Chest pain brought on by physical activity.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03658486

Layout table for location information
United Kingdom
Northern Ireland Cancer Centre, Belfast City Hospital Recruiting
Belfast, United Kingdom, BT9 7JL
Contact: Suneil Jain, PhD    44289097 ext 2180   
Contact: Malcolm Brown, PhD    44289097 ext 2434   
Sponsors and Collaborators
Queen's University, Belfast
HSC Public Health Agency
Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Gillian Prue, Senior Lecturer, Queen's University, Belfast Identifier: NCT03658486    
Other Study ID Numbers: B18/15
First Posted: September 5, 2018    Key Record Dates
Last Update Posted: April 5, 2019
Last Verified: April 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Gillian Prue, Queen's University, Belfast:
Metastatic castrate-resistant prostate cancer
Additional relevant MeSH terms:
Layout table for MeSH terms
Prostatic Neoplasms
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Prostatic Diseases